# DESCRIPTION

## INCORPORATION OF THE SEQUENCE LISTING

- incorporate sequence listing

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND

- describe GHRH
- describe role of GHRH in cancer and pulmonary fibrosis

## SUMMARY

- disclose GHRH antagonists
- disclose methods of treating pulmonary fibrosis and cancer

## DETAILED DESCRIPTION

- disclaim limitations of embodiments
- describe scope of disclosure

### Definitions

- define "comprising"
- define singular forms
- define "or"
- define "optional"
- define "sample"
- define "subject"
- define "patient"
- define ranges
- define "treating"
- define "fragment"
- define "variant"
- define "amelioration"
- define "inhibit"

### Compositions

- define GHRH receptor antagonists
- describe GHRH receptor antagonists as peptides
- provide examples of GHRH analogs
- describe uses of GHRH receptor antagonists
- define GHRH antagonist formula I
- define GHRH antagonist formula II
- describe specific GHRH antagonists
- define terms related to peptides
- describe modification of GHRH peptides for stability
- describe formulation of compositions for administration
- define methods of treatment
- specify tumor types
- describe GHRH antagonists
- outline methods of inhibiting tumor growth
- describe methods of treating cancer
- disclose methods of treating pulmonary fibrosis
- describe methods of reducing lung inflammation
- outline methods of reducing lung scarring
- describe methods of ameliorating symptoms of pulmonary fibrosis
- disclose methods of reducing expression of T cell receptor complex genes
- describe administration and dosage of GHRH receptor antagonists
- introduce compositions
- describe androgen deprivation therapy
- list androgen receptor antagonists
- describe inhibitor of androgen synthesis
- list GnRH agonists
- list GnRH antagonists
- describe chemotherapeutic agents
- list standard of care chemotherapeutic regimens
- describe radiation therapy
- describe immunotherapeutic agents
- describe regulators of programmed cell death
- describe surgery
- describe treatment after surgery
- describe other agents
- define pharmaceutical compositions
- describe composition components
- explain pharmaceutically acceptable carriers
- discuss excipients and their roles
- outline administration routes and methods
- describe formulation for oral or parenteral administration
- discuss preparation for parenteral administration
- explain preparation for oral administration
- describe effective amounts of GHRH antagonists
- outline desired responses to treatment
- discuss dosing parameters and ranges
- provide specific dose ranges and amounts
- mention administration to non-human mammals

## EXAMPLES

### Example 1: Synthesis of GHRH Antagonists

- introduce synthesis of GHRH antagonists
- describe Fmoc-chemistry synthesis method
- detail synthesis of AVR-235
- detail synthesis of AVR-354
- describe synthesis of C-terminal amide compounds
- detail synthesis of AVR-333, AVR-352, and AVR-353
- summarize synthesis of various AVR compounds

### Example 2: Evaluation of Inhibitory Effects of GHRH Antagonists In Vitro

- introduce cell culture and cell viability assay
- describe in vitro cell viability assay
- present inhibitory effects of AVR compounds
- summarize inhibitory potency of AVR compounds

### Example 3: Evaluation of Tumor Inhibitory Activity of GHRH Antagonists In Vivo

- introduce xenograft models of human cancers in nude mice
- describe in vivo tumor inhibitory activity assay
- present inhibitory effects of AVR compounds on tumor growth

### Example 4: Binding Affinities of AVR GHRH Antagonists

- describe receptor binding affinities of AVR GHRH antagonists

### Example 5: Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis Due to Bleomycin

- introduce GHRH receptor antagonist MIA-602
- describe experimental design
- synthesize MIA-602
- describe experimental animals
- administer bleomycin and MIA-602
- prepare tissue samples
- quantify lung inflammation
- measure hydroxyproline content
- perform micro-CT scans
- isolate lung fibroblasts
- measure oxygen consumption
- perform RNA isolation
- analyze RNAseq data
- perform pathway enrichment analysis
- analyze data
- present micro-CT scan results
- present lung hydroxyproline content results
- present lung histopathology results
- present lung fibroblast response to MIA-602
- discuss implications for fibrosing lung diseases

